Unrequited love drove a 57-year-old man to an AI. Delusions of grandeur followed.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $2.94, moving -6.67% from the previous trading session. This change lagged the S&P 500's daily loss of 1.67%. At the same time, ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that ...

We recently published a list of 10 Firms Kick Off Monday Leading Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms ...

We recently published a list of the Top 10 AI Stocks Buzzing on Latest News. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Recursion Pharmaceuticals(NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains appeared ...